Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7220
Abstract: Activating mutations in HER2 are found in approximately 2-4% of non-small cell lung cancer (NSCLC). Recurrent activating mutations most commonly occur in the tyrosine kinase domain (TKD) encoded by exons 18-21, with exon 20 insertions… read more here.
Keywords: tkd mutations; cancer; tkd; her2 ... See more keywords